Vaccine Recommendations of the ACIP
Advisory Committee for Immunization Practices (ACIP)
Zoster (Shingles) ACIP Vaccine Recommendations
as Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
These MMWR publications were published in addition to the official zoster CDC recommendations (listed in the above section) and serve as updates until those recommendations are revised and republished. These MMWRs contain important changes or supplemental recommendations that may include policy notes, changes or updates to recommendations, and notices to readers.
NOTE: As a general rule, if the official recommendations (above section) are dated later than the supplemental recommendations (listed below), the official recommendations override the older items listed below.
- MMWR, November 11, 2011, Vol 60, #44
Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years
Print version [1.32MB, 36 pages]
For your convenience, these archived publications can be used for historical and research purposes.
- None at this time
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.